ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.
|
31284467 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we outline the importance of PI3K/AKT/mTOR signaling pathway in OC tumorigenesis, proliferation and progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR pathway inhibitors in OC.
|
31128298 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.
|
30755818 |
2019 |
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Notably, peptide 17, a YAP inhibitor, exerted a significant attenuating effect on OC progression by diminishing the activation of the PI3K/Akt/mTOR pathway in vitro as well as in vivo.
|
31638241 |
2019 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Interaction between PIK3CA rs3976507 and rs6443626 loci, and factors such as BMI, number of liveborn, tobacco, alcohol, and family history of ovarian cancer are associated with ovarian cancer risk.
|
31288947 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR signaling pathway is considered as a promising therapeutic target in the treatment of ovarian cancer (OC); however, inhibition of this pathway only exhibited moderate clinical efficacy when tested clinically.
|
30972187 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
CEMIP promotes ovarian cancer development and progression via the PI3K/AKT signaling pathway.
|
30925458 |
2019 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Likewise, the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is also a central regulator of the ovarian cancer.
|
29401696 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
These data suggested that PI3K induced epithelial-to-mesenchymal transition and promoted cell migration and invasion by activating the PI3K/AKT pathway in ovarian cancer.
|
30245957 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer.
|
29743815 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Activation of the FOXM1 signaling pathway and the PI3K/AKT/mTOR signaling pathway is associated with poor prognosis in ovarian cancer.
|
30129654 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here we identified the molecular mechanism that limits the efficacy of the beta-sparing PI3Ki, Taselisib (GDC0032), in PIK3CA-mutated OC cell lines (IGROV1 and OAW42) that acquired resistance to GDC0032.
|
30237504 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Prucalopride Inhibits Proliferation of Ovarian Cancer Cells via Phosphatidylinositol 3-Kinase (PI3K) Signaling Pathway.
|
29909423 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.
|
29930760 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The current results highlight the role of miR‑381‑mediated regulation of PIK3CA in the development and progression of ovarian cancer and suggest that restoration of miR‑381 to normal levels in ovarian cancer cells may constitute a therapeutic strategy for patients.
|
30542723 |
2018 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Activation of the PI3K/mTOR pathway has been shown to be correlated with resistance to chemotherapy in ovarian cancer.
|
29371953 |
2017 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
miR-214 targets the PTEN-mediated PI3K/Akt signaling pathway and regulates cell proliferation and apoptosis in ovarian cancer.
|
29113199 |
2017 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
CAF: cancer-associated fibroblasts; COG: Cluster of Orthologous Groups; DEA: disease enrichment analysis; EOC: epithelial ovarian carcinoma; ESCC: oesophageal squamous cell carcinoma; GSI: gamma secretase inhibitor; GO: Gene Ontology; GSEA: gene set enrichment analyzes; HAS: Hungarian Academy of Sciences; lncRNAs: long non-coding RNAs; MAPK/ERK: mitogen-activated protein kinase/extracellular signal-regulated kinases; NGS: next-generation sequencing; ncRNAs: non-coding RNAs; OvC: ovarian cancer; PI3K/Akt/mTOR: phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin; RT-PCR: real-time polymerase chain reaction; SNP: single nucleotide polymorphism; TF: transcription factor; TGF-β: transforming growth factor-β.
|
28574782 |
2017 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Effects of Per2 overexpression on growth inhibition and metastasis, and on MTA1, nm23-H1 and the autophagy-associated PI3K/PKB signaling pathway in nude mice xenograft models of ovarian cancer.
|
27082164 |
2016 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We also found that an activating (E545K) Pik3ca mutation, unlike Pten inactivation or Pik3ca H1047R mutation, cannot cooperate with Arid1a loss to promote ovarian cancer development in the mouse.
|
26279473 |
2016 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Co-targeting IKKβ and PI3K pathways downstream of GAB2 might be a promising therapeutic strategy for ovarian cancer that overexpresses GAB2.
|
26657155 |
2016 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
|
26909613 |
2016 |
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways.
|
26983899 |
2016 |
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
|
27681437 |
2016 |
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
|
26159849 |
2015 |